PURPOSE: Previous clinical studies have indicated that natural IgM antibodies have the ability to induce apoptosis of tumor cells but IgE and IgA may also mediate tumor cell killing (in addition to IgG). The aim of the study was to analyse induction of IgM, IgA and IgE antibodies in patients vaccinated with the tumor associated antigen CEA. METHODS:Twenty-four resected CRC patients without macroscopic disease were immunized seven times with CEA ± GM-CSF. Four different dose schedules were used over a 12-month period. IgM, IgA and IgE antibody responses against recombinant CEA were determined by ELISA. Patients were monitored immunologically for 36 months and clinically for 147 months. RESULTS: GM-CSF significantly augmented the anti-CEA response for all three antibody classes. Low dose of CEA tended to induce a higher IgM, IgA or IgE anti-CEA antibody response than higher. Anti-CEA IgA antibodies could lyse CEA positive tumor cells in antibody dependent cellular cytotoxicity (ADCC) as well as in complement dependent cytotoxicity (CDC). A significant correlation between survival and high IgAanti-CEA titers was noted (p = 0.02) irrespective of GM-CSF treatment. CONCLUSIONS: The observation that IgA anti-CEA antibodies were cytotoxic and associated with improved survival might indicate that also these antibodies may exert a clinical anti-tumor effect.
RCT Entities:
PURPOSE: Previous clinical studies have indicated that natural IgM antibodies have the ability to induce apoptosis of tumor cells but IgE and IgA may also mediate tumor cell killing (in addition to IgG). The aim of the study was to analyse induction of IgM, IgA and IgE antibodies in patients vaccinated with the tumor associated antigen CEA. METHODS: Twenty-four resected CRC patients without macroscopic disease were immunized seven times with CEA ± GM-CSF. Four different dose schedules were used over a 12-month period. IgM, IgA and IgE antibody responses against recombinant CEA were determined by ELISA. Patients were monitored immunologically for 36 months and clinically for 147 months. RESULTS:GM-CSF significantly augmented the anti-CEA response for all three antibody classes. Low dose of CEA tended to induce a higher IgM, IgA or IgE anti-CEA antibody response than higher. Anti-CEA IgA antibodies could lyse CEA positive tumor cells in antibody dependent cellular cytotoxicity (ADCC) as well as in complement dependent cytotoxicity (CDC). A significant correlation between survival and high IgA anti-CEA titers was noted (p = 0.02) irrespective of GM-CSF treatment. CONCLUSIONS: The observation that IgA anti-CEA antibodies were cytotoxic and associated with improved survival might indicate that also these antibodies may exert a clinical anti-tumor effect.
Authors: Gustav J Ullenhag; Jan-Erik Frödin; Karin Strigård; Håkan Mellstedt; Carl G M Magnusson Journal: Cancer Res Date: 2002-03-01 Impact factor: 12.701
Authors: H Schrewe; J Thompson; M Bona; L J Hefta; A Maruya; M Hassauer; J E Shively; S von Kleist; W Zimmermann Journal: Mol Cell Biol Date: 1990-06 Impact factor: 4.272
Authors: Stephanie Brändlein; Judith Lorenz; Nele Ruoff; Frank Hensel; Ines Beyer; Justus Müller; Konrad Neukam; Bertram Illert; Matthias Eck; Hans Konrad Müller-Hermelink; H Peter Vollmers Journal: Hum Antibodies Date: 2002
Authors: Michael Dechant; Gestur Vidarsson; Bernhard Stockmeyer; Roland Repp; Martin J Glennie; Martin Gramatzki; Jan G J van De Winkel; Thomas Valerius Journal: Blood Date: 2002-08-08 Impact factor: 22.113
Authors: Sophia N Karagiannis; Marguerite G Bracher; James Hunt; Natalie McCloskey; Rebecca L Beavil; Andrew J Beavil; David J Fear; Richard G Thompson; Nicholas East; Frances Burke; Robert J Moore; David D Dombrowicz; Frances R Balkwill; Hannah J Gould Journal: J Immunol Date: 2007-09-01 Impact factor: 5.422
Authors: Barbara Platzer; Kutlu G Elpek; Viviana Cremasco; Kristi Baker; Madeleine M Stout; Cornelia Schultz; Eleonora Dehlink; Kai-Ting C Shade; Robert M Anthony; Richard S Blumberg; Shannon J Turley; Edda Fiebiger Journal: Cell Rep Date: 2015-03-05 Impact factor: 9.423
Authors: Javier Sánchez Ramírez; Yanelys Morera Díaz; Mónica Bequet-Romero; Francisco Hernández-Bernal; Katty-Hind Selman-Housein Bernal; Ana de la Torre Santos; Eduardo Rafael Santiesteban Álvarez; Yenima Martín Bauta; Cimara H Bermúdez Badell; Josué de la Torre Pupo; Jorge V Gavilondo; Marta Ayala Avila Journal: BMC Immunol Date: 2017-07-26 Impact factor: 3.615
Authors: Javier Sánchez Ramírez; Yanelys Morera Díaz; Mónica Bequet-Romero; Francisco Hernández-Bernal; Yenima Martín Bauta; Katty-Hind Selman-Housein Bernal; Ana Victoria de la Torre Santos; Mariela Pérez de la Iglesia; Lian Trimiño Lorenzo; Marta Ayala Avila Journal: BMC Immunol Date: 2020-03-14 Impact factor: 3.615